2022. Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s67. DOI:https://doi.org/10.25251/skin.6.supp.67.